Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo

469.563 - 489.767 Dr. Andrea Apolo

need a little bit more therapy in the adjuvant setting, even if they achieved a pathologic complete response. But I would have designed it more adaptively. And if the patients didn't respond, I don't think I would have continued adjuvant dervalumab because would there be I don't think there would be a good rationale to continue a therapy that didn't work in the neoadjuvant setting.